Glucopet

Glucopet is a radiopharmaceutical product containing the active ingredient fludeoxyglucose (18F) supplied as an injectable solution. It is administered intravenously and is used primarily in positron emission tomography (PET) imaging to assess metabolic activity in various tissues. The preparation is prescription‑only and marketed within the European Union for diagnostic purposes across oncology, cardiology, and neurology.

Glucopet is indicated for PET imaging procedures that require visualization of glucose metabolism. It helps clinicians evaluate disease presence and activity in several clinical settings.

- Oncologic PET imaging to detect and stage malignant tumors. - Cardiac PET imaging for assessment of myocardial viability and perfusion. - Neurological PET imaging to investigate epilepsy, dementia, and brain metabolism disorders. - Whole‑body PET scans for metastatic disease evaluation. - Research applications involving metabolic pathway studies.

Adverse reactions to Glucopet are generally mild but can include both common and serious events.

Common: - Transient flushing or warmth at the injection site. - Mild nausea or vomiting. - Short‑duration headache. - Temporary dizziness or light‑headedness.

Serious: - Severe allergic reaction (anaphylaxis) with rash, bronchospasm, or hypotension. - Significant radiation‑induced tissue injury in rare cases.

Glucopet should be used with careful consideration of patient‑specific factors and procedural requirements.

- Verify patient identity and confirm indication before administration. - Assess for known hypersensitivity to radiopharmaceuticals or any component of the formulation. - Use the lowest effective radioactive dose consistent with diagnostic quality. - Pregnant or breastfeeding patients should only receive Glucopet when the potential benefit outweighs the risk. - Ensure proper radiation safety measures for staff and environment. - Review recent imaging studies to avoid unnecessary repeat exposure.

Glucopet may interact with other agents that affect glucose metabolism or radiation exposure.

Avoid: - Concurrent administration of high‑dose glucose or insulin that could alter tracer uptake. - Use of other radiopharmaceuticals within a short interval that may cause cumulative radiation dose.

Use with caution: - Medications that significantly modify blood glucose levels (e.g., corticosteroids, antidiabetic drugs). - Contrast agents used in CT that may affect PET/CT image interpretation. - Chemotherapeutic agents that influence tumor metabolism. - Substances that affect renal clearance, potentially altering tracer distribution.